Click a keyword to view all the abstracts on this site tagged with that keyword.
- Connective tissue diseases and rheumatoid arthritis (RA)
- Connective tissue diseases and sarcoidosis
- connective tissue diseases and systemic lupus erythematosus (SLE)
- connective tissue diseases and systemic sclerosis
- connective tissue diseases and vasculitis
- consults
- consults and education
- consults and gout
- consults and patient-reported outcome measures
- Contractures
- Copd
- Copd and osteoporosis
- copd and vasculitis
- coping
- Coping skills
- Coping skills and fibromyalgia
- Coronary Aneurysm
- Coronary Aneurysm and Kawasaki disease
- coronary artery disease
- coronary artery disease and gout
- coronary artery disease and lupus nephritis
- coronary artery disease and osteoprotegerin
- coronary artery disease and psoriatic arthritis
- coronary artery disease and rheumatoid arthritis
- coronary artery disease and rheumatoid arthritis (RA)
- coronary artery disease and systemic lupus erythematosus (SLE)
- corticosteroids
- Corticosteroids and giant cell arteritis
- corticosteroids and glucocorticoids
- corticosteroids and gout
- corticosteroids and hip disorders
- corticosteroids and immunosuppressants
- Corticosteroids and infection
- corticosteroids and interferons
- corticosteroids and intima medial thickness
- corticosteroids and juvenile dermatomyositis
- corticosteroids and osteoarthritis
- corticosteroids and osteonecrosis
- Corticosteroids and pain
- Corticosteroids and rheumatoid arthritis
- corticosteroids and rheumatoid arthritis (RA)
- corticosteroids and rituximab
- Corticosteroids and systemic lupus erythematosus (SLE)
- corticosteroids and treatment
- corticosteroids and treatment options
- corticosteroids and uveitis
- corticosteroids and vasculitis
- Cost containment
- Cost containment and etanercept
- cost containment and health care cost
- cost containment and high risk
- cost containment and inflammatory arthritis
- cost containment and infliximab
- cost containment and laboratory tests
- cost containment and primary care
- cost containment and psoriatic arthritis
- cost containment and remission
- cost containment and rheumatic disease
- cost containment and rheumatoid arthritis (RA)
- Cost containment and systemic lupus erythematosus (SLE)
- cost containment and trainee
- Counseling
- COX inhibitors
- Creatinine kinase
- Critical care
- CRMO
- CRMO and canakinumab
- Crohn's Disease
- cross-sectional studies
- cross-sectional studies and patient outcomes
- Cryofibrinogen
- Cryofibrinogenemia
- Cryoglobulinemia
- cryoglobulinemia and parvovirus B19
- cryoglobulinemia and rheumatoid arthritis (RA)
- Cryoglobulinemia and vasculitis
- Crystal-induced arthritis
- crystal-induced arthritis and degenerative arthritis
- Crystal-induced arthritis and genetics
- crystal-induced arthritis and gout
- crystal-induced arthritis and hyperuricemia
- crystal-induced arthritis and inflammasome activation
- crystal-induced arthritis and osteoarthritis
- crystal-induced arthritis and prednisolone
- crystal-induced arthritis and quality improvement
- crystal-induced arthritis and shoulder disorders
- Crystal-induced arthritis and synovial fluid
- crystal-induced arthritis and ultrasound
- CTLA-4
- Curriculum
- Curriculum and education
- Curriculum and systemic lupus erythematosus (SLE)
- Curriculum and ultrasound
- cutaneous lupus
- cutaneous lupus and innate immunity
- cutaneous lupus and nephritis
- Cutaneous lupus erythematosus
- Cutaneous lupus erythematosus and dermatomyositis
- cutaneous lupus erythematosus and interferons
- cutaneous lupus erythematosus and population studies
- cutaneous lupus erythematosus and race/ethnicity
- cutaneous lupus erythematosus and systemic lupus erythematosus (SLE)
- Cutaneous manifestations
- cutaneous manifestations and dermatomyositis
- cutaneous manifestations and environmental factors
- cutaneous manifestations and juvenile SLE
- Cutaneous manifestations and polyarteritis nodosa
- cutaneous manifestations and security
- Cutaneous manifestations and systemic lupus erythematosus (SLE)
- Cutaneous manifestations and vasculitis
- CVID
- cyclooxygenase
- cyclooxygenase and prostaglandins
- cyclophosphamide
- cyclophosphamide and infection
- Cyclophosphamide and mycophenolate mofetil
- cyclophosphamide and outcomes
- cyclophosphamide and safety
- cyclophosphamide and systemic lupus erythematosus (SLE)
- cyclophosphamide and tuberculosis
- Cyclophosphamide and vasculitis
- cyclosporine
- cyclosporine and lupus nephritis
- cyclosporine and safety
- CyTOF
- CyTOF and integrins
- CyTOF and scleroderma
- CyTOF and systemic lupus erythematosus (SLE)
- cytokines
- Cytokines and dermatomyositis
- cytokines and environmental factors
- cytokines and exercise
- cytokines and familial Mediterranean fever
- Cytokines and fibroblasts
- cytokines and flow cytometry
- cytokines and genetic disorders
- Cytokines and genomics
- cytokines and giant cell arteritis
- cytokines and glomerulonephritis
- cytokines and heart block
- cytokines and immunoglobulin (IG)
- cytokines and inflammasome activation
- cytokines and inflammation
- cytokines and inflammatory arthritis
- cytokines and interferons
- cytokines and interleukins (IL)
- cytokines and juvenile arthritis
- cytokines and juvenile dermatomyositis
- cytokines and longitudinal studies
- cytokines and lupus nephritis
- Cytokines and macrophage activation syndrome
- cytokines and metabolism
- cytokines and microbiome
- cytokines and monocytes
- cytokines and mouse model
- cytokines and mTor
- cytokines and mucosal T cells
- cytokines and myositis
- cytokines and neonatal disorders
- cytokines and neuropsychiatric disorders
- cytokines and osteoarthritis
- Cytokines and osteoclasts
- Cytokines and osteoporosis
- Cytokines and plasma cells
- Cytokines and polymyositis/dermatomyositis (PM/DM)
- cytokines and posterior reversible encephalopathy syndrome
- cytokines and proteinuria
- cytokines and psoriasis
- cytokines and psoriatic arthritis
- cytokines and questionnaires
- cytokines and regulatory cells
- cytokines and rheumatic disease
- cytokines and rheumatoid arthritis
- cytokines and rheumatoid arthritis (RA)
- cytokines and salivary gland
- cytokines and signal transduction
- cytokines and spine involvement
- cytokines and spondylarthritis
- cytokines and statins
- cytokines and synovial cells
- cytokines and synovitis
- cytokines and systemic lupus erythematosus (SLE)
- cytokines and systemic sclerosis
- Cytokines and takayasu arteritis
- cytokines and therapeutic targeting
- cytokines and tocilizumab
- cytokines and toll-like receptors
- cytokines and transcription factor
- Cytokines and vasculitis
- Data analysis
- data analysis and data collection
- data analysis and fibromyalgia
- data analysis and gout
- data analysis and psoriatic arthritis
- data analysis and synovium
- data analysis and systemic lupus erythematosus (SLE)
- data collection
- data collection and registry
- data collection and rheumatoid arthritis (RA)
- death